Search

Dental amalgam, causes perturbation in photon dose distribution of head and neck (H&N) radiotherapy. The aim of this study was to evaluate the effects of dental amalgam on dose distribution of H&N radiotherapy and accuracy of dose calculations algorithm of commercial treatment planning system (TPS). In this study, the measurements were performed using a constructed H&N anthropomorphic. The sample of healthy teeth and teeth filled by amalgam inserted in the desired segment of the phantom in turn. After scanning and organs segmentation of phantom, intensity-modulated radiation therapy (IMRT) plan including 7 fields in the absence (plan 1) and presence (plan 2) of dental amalgam were created separately. Phantom was irradiated using 6 MV linear accelerator (SIMENS-ARTISTE, 5918). Assessment of the effects of dental amalgam on dose distribution and the accuracy of dose calculation algorithm of TPS was done by measurement and comparing of organ's received dose using thermoluminescent dosimeter (TLDs), placed on a phantom and TPS calculations. The scattering and attenuation due to the presence of dental amalgam led to an increase in parotid glands received dose (up to 24.38%) and a decrease in mean dose (up to -6.25%) PTV70. Results of this study revealed that discrepancies between the collapsed cone convolution (CCC) algorithm calculations Prowess Panther TPS and TLD measurements were -19.77% to 27.49% in presence of amalgam and -1.09% to 5.03% in presence of healthy teeth in phantoms. Attenuation and scattering due to amalgam in IMRT of H&N cancer may lead to a significant dose perturbation which is not predictable by dose calculation of TPS.

The aim of the present study is to investigate folic acid and BSA decorated gold nanoclusters (FA-AuNCs) effect on the enhancement of intracranial C6 glioma tumors radiation therapy (RT) efficacy. Inductively coupled plasma optical emission spectrometry (ICP-OES) measurements exhibited about 2.5 times more FA-AuNCs uptake by C6 cancer cells (32.8 ng/106 cells) than the normal cells. FA-AuNCs had significantly higher concentration in the brain tumors (8.1 μg/mg) in comparison with surrounding normal brain tissue (4.3 μg/mg). Moreover, FA-AuNCs exhibited dose enhancement factor (DEF) of 1.6. The glioma-bearing rats' survival times were almost doubled at radiation therapy + FA-AuNCs (25.0 ± 1.5 days) in comparison with no-treatment group (12.8 ± 0.7 days). The Ki-67 labeling index was 48.89% ± 9.93 for control, 29.98% ± 8.32 for RT, and 11.53% ± 7.65 for RT + FA-AuNCs. Therefore, FA-AuNCs can be effective radiosensitizers for intracranial glioma tumors RT.